[ACL] Alcon Inc

Symbol: ACL Last Price: 170.93 Change: +0.55 (+0.32%) Website: click here

- Guides FY08 $6.48-6.54 v $6.44e (versus $6.39-6.49 on 4/23 and $6.24-6.30 on 2/6), R $6.46-6.51B v $6.4Be v $6.29e (versus R $6.40-6.50B on 4/23 and $6.17-6.27B on 2/6).

Other headlines for [ACL]

• FMS 8/5/2008 08:51am
  Fresenius Medical Hearing FMS, ELN, BVN, MTL mentioned as new sells by Louis Navellier's Global Growth newsletter; EURX, ACL, KOF, IPCR, SDTH mentioned as new buys- WTI mentioned as new sell by Louis Navellier's more...
  
• ACL 7/23/2008 06:03pm
  Alcon Inc Reports Q2 $1.88 v $1.74e, R $1.74B v $1.68Be, raises FY08 guidance- Guides FY08 $6.48-6.54 v $6.44e (versus $6.39-6.49 on 4/23 and $6.24-6.30 on 2/6), R $6.46-6.51B v $6.4Be v $6.29e (versus R more...
  
• ACL 7/14/2008 08:49am
  Alcon Inc Merrill Lynch maintains buy rating, Price target $178- Firm believes ACL's sales and EPS estimates will not be impacted due to discontinuation of two Phase III studies (C-02-60 A and B) that were more...
  
• ACL 7/12/2008 07:56am
  Alcon Inc Terminates development of anecortave acetate for macular degeneration- ACL Friday states it has terminated the development program designed to evaluate the benefit of anecortave acetate treatment on more...
  

Healthcare sector headlines

• CYBX Today 03:06pm
  Cyberonics, Inc Weakness attributed to analyst comment raising concerns over Medicare reimbursements for epilepsy treatment device- a Stanford Group analyst noted that an advisory panel met yesterday to discuss a more...
  
• NVO Today 02:53pm
  Novo Nordisk A/S FDA discloses approval for NovoLog Mix 50/50 (insulin aspart protamine and insulin aspart) Injectable Suspension
  
• BRL Today 12:19pm
  Barr Pharmaceuticals Inc Subsidiary receives approval for generic version of Razadyne tablets- Co. received final approval from the U.S. FDA to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne, 4 more...
  
• THR.BE Today 12:07pm
  ThromboGenics Reports H108 Rev €30.3M; Appoints Dr. Patrik De Haes CEO- As of June 30, 2008, ThromboGenics had €40.4M in cash and cash equivalents. - Co. expects to see an increase in its operating expenses in more...
  
• HITK Today 11:54am
  Hi-Tech Pharmacal Update: Files suit to confirm market exclusivity status regarding Dorzolamide and Timolol Ophthalmic Solution- Note: dorzolamide and timolol ophthalmic solution is the generic for Merck's Cosopt